Collectively, our work highlights that targeting Akt is a viable approach to treat HCC and PP2A activation using small molecule modulators of this phosphatase has the potential as a new targeted approach for HCC treatment. The gene discussed is AKT1; the disease is hepatocellular carcinoma.